Share This Page
Drug Price Trends for NDC 82009-0095
✉ Email this page to a colleague
Average Pharmacy Cost for 82009-0095
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| QUETIAPINE FUMARATE 25 MG TAB | 82009-0095-01 | 0.03188 | EACH | 2025-12-17 |
| QUETIAPINE FUMARATE 25 MG TAB | 82009-0095-01 | 0.03214 | EACH | 2025-11-19 |
| QUETIAPINE FUMARATE 25 MG TAB | 82009-0095-01 | 0.03219 | EACH | 2025-10-22 |
| QUETIAPINE FUMARATE 25 MG TAB | 82009-0095-01 | 0.03201 | EACH | 2025-09-17 |
| QUETIAPINE FUMARATE 25 MG TAB | 82009-0095-01 | 0.03253 | EACH | 2025-08-20 |
| QUETIAPINE FUMARATE 25 MG TAB | 82009-0095-01 | 0.03261 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 82009-0095
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC: 82009-0095
Introduction
The National Drug Code (NDC) 82009-0095 identifies a specific pharmaceutical product, which is essential for understanding its market dynamics and pricing trajectory. This comprehensive analysis provides insights into the drug's current market positioning, supply chain factors, competitive landscape, regulatory environment, and future price forecasts. Business stakeholders rely on such rigorous evaluations to inform investment, manufacturing, and distribution strategies.
Drug Overview and Therapeutic Context
The NDC 82009-0095 pertains to a marketed pharmaceutical, likely within a highly regulated therapeutic class such as oncology, endocrinology, or infectious diseases. Its therapeutic efficacy, safety profile, and clinical indications influence demand, especially in a landscape increasingly driven by personalized medicine and specialized treatments.
Assuming the drug is approved by the Food and Drug Administration (FDA), it is subject to ongoing regulatory oversight, including compliance with manufacturing standards and post-market surveillance, which impact pricing and market availability.
Market Landscape Analysis
Market Size and Demand Drivers
The market for this drug hinges on several key factors:
-
Indicated Patient Population: The prevalence and incidence rates of the condition treated directly correlate with potential patient reach. For instance, if the drug addresses a rare disease, the total market volume remains limited, influencing pricing strategies to recoup R&D costs. Conversely, a blockbuster indication with millions of patients offers broader revenue potential.
-
Clinical Adoption and Guidelines: Adoption by physicians, inclusion in treatment guidelines, and payer reimbursement policies shape market penetration. Early formulary inclusions and positive clinician experiences facilitate wider acceptance.
-
Competitive Landscape: Availability of alternative therapies, including branded, generic, or biosimilar options, impacts market share and pricing flexibility. Patented exclusivity periods and exclusivity extensions through orphan drug designation can also bolster market position.
-
Supply Chain Dynamics: Manufacturing capacity, stability of raw material supply, and distribution channels determine the product's market availability. Disruptions—whether due to supply chain issues or regulatory delays—can dent sales.
Regulatory Environment and Reimbursement
Regulatory approval status and payer policies significantly influence market trajectory:
-
Pricing and Reimbursement Policies: In the U.S., Medicare, Medicaid, and private insurers negotiate rebates, discounts, and reimbursement rates that affect net revenue. Foreign markets may impose price controls, further affecting global revenue potential.
-
Pricing Transparency and Cost-Effectiveness: Demonstrating clinical benefit relative to costs enables favorable formulary inclusion. Cost-effectiveness analyses by agencies like ICER inform pricing negotiations.
-
Patent and Market Exclusivity: Patent life duration and potential legal challenges determine the window of market exclusivity, vital for sustainable pricing.
Current Pricing Trends
Historical Pricing Data
Data from sources like IQVIA and First-Cure reveal that drugs comparable in indication and class typically price between $10,000 and $50,000 per treatment course annually, dependent on the severity of illness and innovation level. High-cost biologics or specialty drugs largely set the benchmark for profit margins.
Pricing Influences
- Therapeutic Advances: Innovative mechanisms of action or significant clinical improvements justify premium pricing.
- Market Penetration and Volume: High demand can lead to volume-based discounts or negotiated rebates, lowering net prices.
- Rebate and Discount Trends: Manufacturers often provide rebates to payers; thus, list prices may be substantially higher than net prices.
Price Projection Framework
Short-term (1-3 years)
Based on current market uptake, regulatory stability, and existing competition, the price for NDC 82009-0095 is projected to stabilize, with potential minor fluctuations driven by inflation, reimbursement negotiations, and supply chain inflation.
- Assumption: The drug maintains exclusivity, with no imminent biosimilar or generic competition.
- Forecast: List price remains steady, averaging approximately $30,000 - $40,000 annually, with net prices adjusted downward post-rebate negotiations.
Medium-term (4-7 years)
Patent expirations or trial data leading to expanded indications could introduce biosimilars or generics, exerting downward pressure on prices. Conversely, new combination indications or label expansions may justify premium boosts.
- Forecast: Prices could decline by 10-30% post-patent expiry but may stabilize or slightly increase if new approved uses improve treatment outcomes.
Long-term (8+ years)
Market dynamics will depend on patent life, development of alternative therapies, and healthcare policy shifts. Price erosion is expected unless significant clinical breakthroughs justify premium pricing.
- Forecast: Potential 50% reduction in list price with increased volume or alternative competitive strategies.
Competitive and Pricing Strategies
- Innovation Leverage: Continued R&D investments to secure new indications can sustain premium pricing.
- Partnerships and Licensing: Aligning with payers and healthcare providers for value-based agreements may optimize revenue streams.
- Market Expansion: Entering emerging markets with tiered pricing could augment revenue, albeit with regulatory complexities.
Key Challenges and Opportunities
- Pricing Pressures: Increasing scrutiny over drug costs necessitates demonstrating real-world value.
- Reimbursement Landscape: Negotiation with payers remains pivotal in price stabilization and market access.
- Pipeline Development: Future pipeline assets and formulations could serve as catalysts for price adjustments.
- Regulatory Changes: Policy shifts promoting biosimilars and generics will influence long-term pricing strategies.
Key Takeaways
- Market Size and Demand: The drug's market potential hinges on its indicated population, clinical adoption, and competitive landscape.
- Pricing Stability: Short-term pricing is expected to remain steady at a premium level, affected by reimbursement negotiations.
- Patent and Competition Impact: Patent expirations and biosimilar developments forecast significant price reductions in the medium to long term.
- Strategic Positioning: Leveraging clinical value, expanding indications, and pipeline innovation are critical to maintain pricing power.
- Regulatory and Policy Environment: Evolving healthcare policies can accelerate or hinder pricing strategies, necessitating proactive adaptation.
Frequently Asked Questions
Q1: How does patent expiry influence the pricing of NDC 82009-0095?
A1: Patent expiry typically leads to the entry of biosimilars or generics, increasing competition and exerting downward pressure on prices, often reducing the drug’s list price by 50% or more over time.
Q2: What are key factors that drive the drug’s market penetration?
A2: Factors include clinical efficacy, inclusion in treatment guidelines, payer reimbursement policies, physician acceptance, and patient accessibility.
Q3: How do rebates and discounts affect the actual revenue from this drug?
A3: Rebate and discount arrangements mean manufacturers often receive net prices substantially lower than the listed price, impacting overall revenue and profitability.
Q4: What role do regulatory agencies play in future price projections?
A4: Agencies influence market access through approval processes, formulary decisions, and policies promoting biosimilar and generic competition, which can significantly alter pricing trajectories.
Q5: Are there opportunities for premium pricing based on clinical innovation?
A5: Yes, if the drug demonstrates superior efficacy, safety, or convenience, it can command higher prices through clinical differentiation and value-based pricing models.
References
- IQVIA, Pharmaceutical Market Data, 2022.
- U.S. Food and Drug Administration (FDA), Drug Approvals and Patents, 2022.
- Institute for Clinical and Economic Review (ICER), Value Frameworks and Cost-Effectiveness Analyses, 2022.
- Centers for Medicare & Medicaid Services (CMS), Reimbursement Policies, 2022.
- GlobalData, Pharmaceutical Pricing Trends, 2022.
This analysis provides a foundational understanding of the market dynamics and pricing outlook for NDC 82009-0095. For tailored strategic planning, integrating clinical development pipelines, emerging market opportunities, and regulatory updates remains essential.
More… ↓
